All articles by Staff Writer
Staff Writer
Study Proves iTind Treatment for Enlarged Prostate Lasts More than Four Years
Olympus Corporation, a global medical technology company, announced publication of study data demonstrating that the minimally invasive iTind™ treatment provides long-lasting relief of more than four years for people suffering from the symptoms of an enlarged prostate, also known as BPH.
Gustave Roussy and THERYQ: France welcomes the first FLASH radiotherapy machine to treat patients
Gustave Roussy and THERYQ announce a strategic and structuring partnership to roll out and assess FLASH technology for radiotherapy. French medical technology company THERYQ, specializing in particle accelerators and radiotherapy systems, has provided Gustave Roussy’s Department of Radiotherapy with the first FLASH clinical radiotherapy machine in France for treating superficial tumours.
Medicxi asset-centric portfolio company Versanis Bio to be acquired by Lilly to improve patient outcomes in cardiometabolic diseases
Medicxi asset-centric portfolio company Versanis Bio to be acquired by Lilly to improve patient outcomes in cardiometabolic diseases
Deenova’s Newest Product Line, AIDE, Pursues Successful Launch With New Contract Award at Longjumeau Hospital in France
Deenova, the undisputed leading supplier of innovative pharmacy automation solutions for healthcare facilities, is delighted to announce the recent contract acquisition at Longjumeau Hospital in France, marking another milestone in the successful launch of its cutting-edge product line, AIDE. The contract includes the deployment of one AIDE-CUT, the unparalleled Deenova’s automation robot for medications repackaging in unit dose, and one AIDE-PICK, the most innovative automated patient therapy dispensation robot.
Establishment of Asahi Kasei Healthcare Headquarters in the United States
Asahi Kasei announced that it is moving the global headquarters for its Healthcare Business to the United States. The Primary Executive Officer for Healthcare and staff will be located in existing Asahi Kasei offices in Chelmsford, Massachusetts, a suburb of Boston.
Analysis Showcases Potential for More Complete Revascularizations with Impella Compared to IABP during HRPCI
Abiomed, part of Johnson & Johnson MedTech[1], announces results of a third-party analysis showing that utilizing Impella during high-risk percutaneous coronary intervention (PCI) procedures may help physicians achieve a more complete revascularization compared to high-risk PCIs supported using an intra-aortic balloon pump (IABP). Previous studies have shown that a more complete revascularization can lead to longer survival[2],[3], a greater reduction in heart failure and angina symptoms[4], and an improved quality of life for the patient[5].
Medtronic to present new data on its intelligent dosing platforms at the American Diabetes Association 83rd Scientific Sessions
Medtronic plc (NYSE:MDT), a global leader in medical technology, today announced its participation in the upcoming American Diabetes Association’s (ADA) 83rd Scientific Sessions in San Diego on Jun. 23-26, 2023. During the conference, Medtronic will present new data and clinical outcomes across a broad population of patients from its newly FDA-approved MiniMed™ 780G system with Guardian™ 4 sensor — which began shipping in the U.S. earlier this month — as well as their Extended Infusion Set and InPen™ smart insulin pen.
Medtronic presents new data on MiniMed™ 780G system on fixed meal dosing and real-world Time in Range across wide variety of users
Medtronic plc(opens new window)(NYSE: MDT), a global leader in healthcare technology, is presenting a robust collection of new clinical and real-world data on the MiniMed™ 780G system. These latest data sets, which evaluated the system across a wide range of users, including historically challenging younger patients, those not meeting glycemic goals, and individuals using a simplified meal announcement leveraging fixed carbohydrate amounts instead of exact carb calculations, found that the proprietary Meal Detection™ technology supported Time in Range outcomes that exceed consensus guidelines of 70 percent. Additionally, the system is helping reduce the percent of time spent in hyperglycemia in children and adults. These latest results were presented this weekend at the 83rd American Diabetes Association (ADA) Scientific Sessions in San Diego, CA.
Breakthrough Study Demonstrates that High-Dose Hemodiafiltration Treatment for Kidney Failure Patients Significantly Reduces Mortality Rates
The CONVINCE Trial study compares high-dose hemodiafiltration with standard, high-flux hemodialysis Study revealed a 23% decrease in mortality rates for patients treated with high-volume hemodiafiltration compared to those treated with more commonly used high-flux hemodialysis Exploration of methods to increase adoption of hemodiafiltration (HDF) making this therapeutic option accessible to patients
AOP Health: Completed study strengthens clinical development program for ropeginterferon alpha 2b (BESREMi®) in polycythaemia vera
With the publication of the final results from the LOW-PV study in the New England Journal of Medicine Evidence conducted by Fondazione per la Ricerca dell’Ospedale di Bergamo (FROM) under the leadership of Professor Tiziano Barbui, AOP Health announces an important advancement reinforcing its clinical development program for ropeginterferon alpha-2b (BESREMi®) in polycythaemia vera (PV), a rare blood cancer. The academic LOW-PV study supported and funded by AOP Health and public organizations in Italy complements a series of trials performed by AOP Health over more than 10 years to achieve marketing authorization in Europe and the Middle East. With these clinical studies, including PEGINVERA, PROUD-PV, and CONTINUATION-PV, AOP Health opened a new area of treatment options for patients suffering from PV. A further study (PEN-PV) was performed to develop a pen for self-injection allowing ease of self-administration, exact dosing and minimal waste of the medical product. AOP Health’s comprehensive development program in PV is considered by many key opinion leaders as the most significant development in the field of PV treatment in the past 30 years.